Clinical trial · Observational
Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
NCT01812148CI-TRIAL-00009742completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peritoneal Mesotheliomas | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytoreductive surgery and HIPEC | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Peritoneal Mesotheliomas
- description
- Cytoreductive surgery and HIPEC
- interventionNames
- Procedure: Cytoreductive surgery and HIPEC
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- Disease-Free survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Peritoneal mesothelioma Exclusion Criteria: * Non resectable disease
References
Publications (0)
Data not yet available
No reference posted for this study.